Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (DE:P09)
BERLIN:P09
Holding DE:P09?
Track your performance easily
P09 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€1.10 - €9.24
Previous Close€1.93
Volume0.00
Average Volume (3M)1.13K
Market Cap
€510.34M
Enterprise Value€936.43M
Total Cash (Recent Filing)$471.15M
Total Debt (Recent Filing)$920.75M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Feb 13, 2025EPS Estimate
-€0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding273,863,544
10 Day Avg. Volume5
30 Day Avg. Volume1,130
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.17
Price to Sales (P/S)3.10
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.41
Enterprise Value/Gross Profit17.74
Enterprise Value/Ebitda-3.59
Forecast
1Y Price Target
€2.92Price Target Upside50.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Pacific Biosciences News
PremiumCompany Announcements
Pacific Biosciences Updates Executive Severance Agreements
PremiumCompany Announcements
Pacific Biosciences Appoints CEO as Interim CFO
Bulls Say, Bears Say
Bulls Say
Debt ManagementPacBio's refinancing of a portion of its convertible debt addresses investor concerns related to the company's debt overhang.
Market ExpansionA record number of Onso units were shipped, including two-thirds to new customers, which supports growth into the future.
Product LaunchNew SPRQ chemistry and Vega benchtop long read instrument have needle-moving potential for Pacific Biosciences.
Bears Say
Financial PerformanceThe company's total revenue of $40.0 million was lower than estimates and represented a 28% year-over-year decrease.
Guidance And ExpectationsRevio pushouts and macro headwinds weigh on the quarter, resulting in lower guidance to reflect capex pressure and a longer sales cycle following the Vega launch.
Product CompetitionCannibalization with Revio remains the key question, as the Vega platform will likely be of interest to labs that would consider purchasing a Revio platform.
---
P09 FAQ
What was Pacific Biosciences’s price range in the past 12 months?
Pacific Biosciences lowest stock price was €1.10 and its highest was €9.23 in the past 12 months.
What is Pacific Biosciences’s market cap?
Currently, no data Available
When is Pacific Biosciences’s upcoming earnings report date?
Pacific Biosciences’s upcoming earnings report date is Feb 13, 2025 which is in 46 days.
How were Pacific Biosciences’s earnings last quarter?
Pacific Biosciences released its earnings results on Nov 07, 2024. The company reported -€0.208 earnings per share for the quarter, beating the consensus estimate of -€0.209 by <€0.001.
Is Pacific Biosciences overvalued?
According to Wall Street analysts Pacific Biosciences’s price is currently Undervalued.
Does Pacific Biosciences pay dividends?
Pacific Biosciences does not currently pay dividends.
What is Pacific Biosciences’s EPS estimate?
Pacific Biosciences’s EPS estimate is -€0.19.
How many shares outstanding does Pacific Biosciences have?
Pacific Biosciences has 273,863,560 shares outstanding.
What happened to Pacific Biosciences’s price movement after its last earnings report?
Pacific Biosciences reported an EPS of -€0.208 in its last earnings report, beating expectations of -€0.209. Following the earnings report the stock price went down -19.323%.
Which hedge fund is a major shareholder of Pacific Biosciences?
Among the largest hedge funds holding Pacific Biosciences’s share is ARK Investment Management LLC. It holds Pacific Biosciences’s shares valued at 57M.
---
Pacific Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€2.92 (50.92% Upside)
€2.92 (50.92% Upside)
Blogger Sentiment
Neutral
DE:P09 Sentiment 50%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $172.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.87%
12-Months-Change
Fundamentals
Return on Equity
-64.80%
Trailing 12-Months
Asset Growth
-23.62%
Trailing 12-Months
Company Description
Pacific Biosciences
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
---
P09 Company Deck
---
P09 Earnings Call
Q3 2024
0:00 / 0:00
---
P09 Stock 12 Month Forecast
Average Price Target
€2.92
▲(50.92% Upside)
Technical Analysis
Pacific Biosciences
―
Illumina
―
Becton Dickinson
―
Exact Sciences
―
Fulgent Genetics
―
Best Analysts Covering P09
1 Year
1 Year Success Rate
7/18 ratings generated profit
1 Year Average Return
+17.01%
reiterated a buy rating 2 months ago
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of +17.01% per trade.
---